Strides Pharma Reports Q1FY25 Revenues at Rs. 1,087.5 Crore

The consolidated financial results of Strides Pharma Science for Q1FY25 ended June 30, 2024 show revenues of Rs.1,087.5 crore, compared to Rs. from the same quarter last year. 9,320 crore showing an increase of 16.75 percent compared to the previous year. Q4 FY2024 saw Q-on-Q revenues totaling Rs. 1,058.3 crore resulted in a 2.8 per cent increase.

EBITDA in the first quarter amounted to Rs. Rs. 217 crore was the amount compared to the same quarter last year. 168.6 crore showing an increase of 28.7 per cent. In the fourth quater of financial year 2024 it was Rs. 204 crore and the Q-on-Q growth was 6.4 percent. The reported PAT was Rs. 68. 3 crore. Adjusted PAT from continuing operations without JV share and exceptional items was Rs. 83.9 crore.

Arun Kumar, founder & executive chairperson, and Badree Komandur, MD & group CEO, said,  “Our emphasis on profitability, efficiency and growth has led to a strong performance across markets, allowing us to deliver superior returns ahead of the projected timelines for our FY25 outlook.

The company reached important milestones, including a 20% EBITDA margin, Rs. 683 million of PAT reported and a Debt/EBITDA ratio of 2.3x. They said they are sure they can maintain the momentum by constantly improving the quality of their business.

The pharmaceutical firm stated that their increased emphasis on digitization, automation, and ESG is aimed at improving compliance and business results.